Slide 1: Teleflex Separation and Vascular Intervention Acquisition
Teleflex Incorporated Teleflex Separation and Vascular Intervention Acquisition February 27, 2025
Slide 2: Conference Call Logistics
Conference Call Logistics The release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on Investors) An audio replay of the call will be available beginning at 11:00 am Eastern Time on February 27, 2025 and can be accessed on the Teleflex website or by telepho
Slide 3: Today's Speakers
Today’s Speakers Liam Kelly Thomas Powell John Deren Lawrence Keusch Chairman, Executive VP Corporate VP and VP, Investor President and CEO and CFO Chief Accounting Relations Officer and Strategy Development
Slide 4: Note on Forward-Looking Statements
Note on Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements. Examples of forward-looking statements include statements with respect to the Company's proposed acquisition of Biotronik's Vascular Inter
Slide 5: Teleflex's Value Creation Framework
Teleflex’s Value Creation Framework 1 2 3 4 Drive Sustainable Achieve Margin and Optimize Our Return Capital to Revenue Growth Earnings Expansion Product Portfolio Shareholders Acquisition of BIOTRONIK’s Vascular Drive leverage through Announcing separation of Teleflex Intend to execute on remaining
Slide 6: Executive Summary – Vascular Intervention Acquisition
Executive Summary – Vascular Intervention Acquisition – Announcing acquisition of BIOTRONIK’s Vascular Intervention business, consisting of a broad portfolio of drug- coated balloons, drug-eluting stents, covered stents, self-expanding and balloon-expandable bare metal stents, and balloon catheters
Slide 7: Acquiring a Broad Coronary and Peripheral Product Portfolio
Acquiring a Broad Coronary and Peripheral Product Portfolio Key Segments Representative Products Call Points Coronary Interventional Vascular Cardiology Interventions Orsiro™ Mission PK Papyrus™ Covered Pantera™ Lux™ Drug- Pantera™ Pro DES Coronary Stent Coated Balloon Coronary Balloon Vascular Free
Slide 8: Strengthening The Teleflex Interventional Business
Strengthening The Teleflex Interventional Business – Vascular Intervention acquisition significantly expands Teleflex’s market presence with a combined coronary/ Expanding Into An peripheral Interventional business Attractive Market – The peripheral intervention market is growing rapidly with global
Slide 9: Freesolve RMS: Disruptive potential of resorbable technology
Freesolve™ RMS: Disruptive potential of resorbable technology through potential mitigation of long-term adverse effects BIOMAG-I demonstrated clinical evidence Potential to disrupt on safety existing coronary BIOMAG-II stent (DES) market (ongoing) prospective 4 RCT non-inferiority trial Launch Clini
Slide 10: Vascular Intervention Acquisition Financial Summary
Vascular Intervention Acquisition Financial Summary – Cash payment on closing of approximately €760 million, less certain adjustments as provided in the purchase agreement including certain working capital not transferring and Transaction other customary adjustments – Expected to close by the end of
Slide 11: Teleflex's Value Creation Framework
Teleflex’s Value Creation Framework 1 2 3 4 Drive Sustainable Achieve Margin and Optimize Our Return Capital to Revenue Growth Earnings Expansion Product Portfolio Shareholders Acquisition of BIOTRONIK’s Vascular Drive leverage through Announcing separation of Teleflex Intend to execute on remaining
Slide 12: Separation Designed to Deliver Greater Value for All Stakeholders
– Positions each company to accelerate growth profile with a simplified operating model, streamlined manufacturing footprint and increased management Separation Designed focus to Deliver Greater – Allows better allocation of resources to the unique strengths and opportunities of Value for All each b
Slide 13: Transaction Overview
Transaction Overview – Teleflex to create a new, independent, publicly traded company (“NewCo”) with the following businesses: • Urology: To include Interventional Urology and bladder management portfolio • Acute Care: To include Anesthesia, Respiratory, intra-aortic balloon pump portfolio, and sele
Slide 14: Establishing Two Leading, Focused, Independent Companies
Establishing Two Leading, Focused, Independent Companies RemainCo NewCo – Streamlined portfolio focused on highly – Undivided management focus to unlock NewCo’s complementary product categories – Vascular Access, potential through a simplified operating model Interventional, and Surgical – Establish
Slide 15: Separation Positions Both Businesses For Greater Corporate Clarity
Separation Positions Both Businesses For Greater Corporate Clarity and Enhanced Strategic Focus… RemainCo NewCo 1 2 3 Vascular Access , Interventional, Surgical Urology , Acute Care , OEM Strategic Focus Better positioned to capitalize on high-growth, high-acuity, Ability to identify, invest in, and
Slide 16: With Simplified Operating Models and Streamlined Manufacturing Footprints
…With Simplified Operating Models and Streamlined Manufacturing Footprints – Simplifying operating model from Teleflex’s seven product categories today to three product categories in each company post-separation – NewCo structure, business locations, and manufacturing footprint enable a straightforw
Slide 17: RemainCo to Focus on Highly Complementary Product Categories
RemainCo to Focus on Highly Complementary Product Categories Primarily Within Hospital-Focused End Markets Key Sites of Care / RemainCo 1 1 Market Served Market Growth Call Points Post-Separation Simplified Intensive Care Unit operating model Vascular $4bn 2 MSD Access Emergency Medicine 6%+ constan
Slide 18: RemainCo Will Maintain A Disciplined Capital Allocation Strategy
RemainCo Will Maintain A Disciplined Capital Allocation Strategy Internal Investment Strategic M&A Debt Repayment Cash to Shareholders Prioritize R&D and other Deploy capital for growth- Pay down debt as Teleflex to continue high-ROI projects to drive accretive acquisitions to appropriate to optimiz
Slide 19: NewCo Comprises A Strong Portfolio In Established End Markets
NewCo Comprises A Strong Portfolio In Established End Markets… Key Sites of Care / NewCo 1 1 Market Served Market Growth Call Points Post-Separation Hospital 100% Focus on three businesses Urology $9bn LSD - MSD ASC Physician Office LSD - MSD constant currency Intensive Care Unit revenue growth Acut
Slide 20: With Potential to Accelerate Growth Over the Medium Term
...With Potential to Accelerate Growth Over the Medium Term Pre-2024 2024 - 2026 2027+ • OEM business has a long track • Stabilization of OEM growth following • Focused OEM strategy with flexibility record of durable growth, delivering loss of legacy customer and to further expand customer base, a 9
Slide 21: Teleflex Separation Summary
Teleflex Separation Summary – Teleflex to create a new, independent, publicly traded company (“NewCo”) Transaction comprising Urology, Acute Care, and OEM – Intended to take the form of a distribution of newly issued shares of NewCo to Details shareholders that is tax-free for U.S. tax purposes – Tr
Slide 22: Thank You!
Thank You! Empowering Ihe fulure of healtheare
Slide 23: Appendices
Appendices Empowering the future of healthcare
Slide 24: Product Portfolio Synergies Resulting From Announced Acquisition
Product Portfolio Synergies Resulting From Announced Acquisition Combined Vascular Intervention Portfolio (1) BIOTRONIK's Vascular Synergies Intervention Business ◦ VI acquisition highly complementary to TFX complex PCI portfolio Core Complex Coronary Vascular Peripheral ◦ Allows access to new Inter
Slide 25: BIOTRONIK Vascular Intervention Business At A Glance
BIOTRONIK Vascular Intervention Business At A Glance Total Addressable Market of BIOTRONIK's 2023 Sales Mix of BIOTRONIK's 2 Vascular Intervention Business Vascular Intervention Business Global Coronary Vascular Intervention Market Split By Sales Region Split By Product Area 64% EMEA PVI 51% 26% TAM
Slide 26: Large Global CVI Market and Entry Into Fast-Growing PVI Market
Large Global CVI Market and Entry Into Fast-Growing PVI Market – Cardiovascular disease remains the primary cause of death globally, with percutaneous intervention being the most common therapy for coronary and peripheral artery disease – The current total addressable market related to vascular inte